Are Hedge Funds Betting Against Achillion Pharmaceuticals, Inc. (ACHN)?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) produced a 64.34% rally since recording the worst price of $1.29. Thanks to the latest 2.91% increase, it now trades at $2.12. Throughout the trading on 01/11/2019, the share price floated between $2.02 and $2.14. This company shares are 159.43% off its target price of $5.5 and the current market capitalization stands at $293.8M. The recent change has given its price a -16.15% deficit over SMA 50 and -51.15% deficit over its 52-week high. The stock witnessed -30.49% declines, -29.57% declines and -27.65% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ACHN’s volatility during a week at 7.83%.

Achillion Pharmaceuticals, Inc. (ACHN) Top Holders

Institutional investors currently hold around $230 million or 82.2% in ACHN stock. Look at its top three institutional owners. Rtw Investments, Lp owns $28.82 million in Achillion Pharmaceuticals, Inc., which represents roughly 9.81% of the company’s market cap and approximately 12.53% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 11,925,359 shares of the stock are valued at $25.28 million. The third largest holder is Vanguard Group Inc, which currently holds $24.83 million worth of this stock and that ownership represents nearly 8.45% of its market capitalization.

Achillion Pharmaceuticals, Inc. 13F Filings

At the end of September reporting period, 67 institutional holders increased their position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by some 14,271,101 shares, 53 decreased positions by 14,078,043 and 29 held positions by 80,304,972. That puts total institutional holdings at 108,654,116 shares, according to SEC filings. The stock grabbed 26 new institutional investments totaling 7,847,531 shares while 13 institutional investors sold out their entire positions totaling 3,302,174 shares.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Insider Trades

Multiple company employees have indulged in significant insider trading. Achillion Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Johnson & Johnson has sold 18,367,346 shares of Achillion Pharmaceuticals, Inc. (ACHN) in trading session dated Nov. 20, 2017. These shares are worth $50,510,202 and were traded at $2.75 each. The SEC filing shows that Fisherman Jason S performed a purchase of 10,000 shares. The Director added these shares by way of transaction on Dec. 22, 2016. The company’s shares were assimilated at $3.96 per share worth to an investment of some $39,600 on account of Fisherman Jason S.

CFO, Fenton Mary Kay, purchased 2,500 common shares of Achillion Pharmaceuticals, Inc. (ACHN) in the open market. In a transaction dated Dec. 05, 2016, the shares were bought at an average price of $4.11, giving away a sum of $10,275. After this purchase, 2,500 common shares of ACHN are directly owned by the insider, with total stake valued at $5,300.

In the transaction dated Dec. 02, 2016, the great number of shares acquired came courtesy the Chief Commercial Officer; Truitt Joseph added a total of 3,500 shares at an average price of $4.06, amounting to approximately $14,210. The insider now directly owns 3,500 shares worth $7,420.

Achillion Pharmaceuticals, Inc. (ACHN) Analyst Guide

Several analysts have released their opinion on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), with 2 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation.